Head-to-head evidence
Elacestrant vs Fulvestrant
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline
Elacestrant
Marketed by Stemline Therapeutics, Inc.
NCT03778931 · Phase 3 · completed
This was a large randomized trial comparing elacestrant with active standard-of-care treatment, but it was open-label rather than double-blind. The primary progression-free survival endpoints, assessed by blinded imaging review, were statistically significantly better with elacestrant in both ESR1-mutant and all participants, but the lack of participant and investigator blinding limits the strength of the evidence.
Next expected readout: November 2026 · NCT06691035 (registry estimate)
Fulvestrant · Faslodex
Marketed by AstraZeneca
NCT00635713 · Phase 3 · completed
The trial randomized an estimated 588 participants and used double blinding to compare two active treatment groups: fulvestrant 125 mg plus anastrozole versus fulvestrant 250 mg plus anastrozole. Its primary endpoint was time to tumor progression, a clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: October 2026 · NCT04851613 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Elacestrant's landscape · Fulvestrant's landscape